Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

(Reuters) -Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its ...

NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.

Part of the appeal of amylin analogs is the potential to drive weight loss without causing the same level of tolerability problems as GLP-1 receptor agonists. Lilly reported relatively low rates of ...

Lilly and Novo Nordisk NVO presently dominate the market. Mounjaro and Zepbound face strong competition from Novo Nordisk’s semaglutide medicines, Ozempic for diabetes and Wegovy for obesity.

The therapy is facing stiff competition, biosimilar and otherwise, that is eating into its market share ... only approved medicine that does that is Zepbound, the weight loss therapy marketed ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Discover why Hims & Hers is leading the telehealth market with strong growth, a loyal user base, and expansion into new ...

“With the semaglutide shortage declared over, Hims now has to transition its model to generate growth from other products ...

Eli Lilly will start selling the two highest doses of its popular weight-loss drug Zepbound directly to customers online in ...

Millions of Americans use GLP-1s, and many have relied on versions produced by compounding pharmacies because of the high monthly costs for brand names like Mounjaro and Zepbound.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.